{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:51:33Z","timestamp":1790297493543,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Adherence to therapy is one of the most important elements during the therapeutic process ensuring the predefined therapeutic outcomes. The aim is to analyze the need and importance of treatment adherence guideline for acromegaly patients and the possibilities for its development and implementation in Bulgaria.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A set of methods was applied: (1) a literature review in the electronic database for identification of articles and guidelines related to adherence and acromegaly; (2) analysis of Bulgarian legislative documents; (3) a pilot study for assessment of the level of treatment adherence among hospitalized Bulgarian acromegaly patients in 2018; (4) a plan for development and implementation of specific guideline was created entitled BULMEDACRO - BULgarian guideline for MEdication aDherence assessment and improvement in ACROmegaly.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> No specific guidelines for evaluation, monitoring, reporting and\/or improving adherence in acromegaly patients has been found in the literature. Requirements for regular assessment of the level of adherence, application of appropriate methods for improvement and monitoring are not sufficiently formulated and mandatory. The pilot study confirmed that therapy adherence among Bulgarian patients with acromegaly is relatively high as almost 90% of patients report that they strictly comply with their prescribed treatment regimen. It is necessary, however, a specific guideline focused on the methods for assessment and improvement of adherence, in order to ensure monitoring and follow-up of acromegaly patients.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Patients with acromegaly should be the focus of specially designed national programs, initiatives and\/or guidelines for regular evaluation and improvement of the adherence level. Despite the difficulties and the lack of an adequate legal basis, successive steps initiated by different stakeholder are needed.<\/jats:p>","DOI":"10.3389\/fpubh.2021.693409","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T07:09:56Z","timestamp":1626246596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Do We Need a Specific Guideline for Assessment and Improvement of Acromegaly Patients Adherence?"],"prefix":"10.3389","volume":"9","author":[{"given":"Maria","family":"Kamusheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexina","family":"Parvanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanitsa","family":"Rusenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vandeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanaska","family":"Elenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin Proc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.amjms.2016.01.010","article-title":"Medication adherence: truth and consequences","volume":"351","author":"Brown","year":"2016","journal-title":"Am J Med Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"685696","DOI":"10.3389\/fphar.2021.685696","article-title":"A cross-sectional survey on medication management practices for noncommunicable diseases in Europe during the second wave of the COVID-19 pandemic","volume":"12","author":"\u00c1gh","year":"2021","journal-title":"Front Pharmacol."},{"key":"B4","first-page":"1","volume-title":"Concordance, Adherence and Compliance in Medicine Taking","author":"Horne","year":"2005"},{"key":"B5","unstructured":"Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence. Full Guideline2009"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD000011","DOI":"10.1002\/14651858.CD000011.pub3","article-title":"Interventions for enhancing medication adherence","volume":"2014","author":"Haynes","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-19-0124","article-title":"Individualised management of acromegaly","volume":"181","author":"Bollerslev","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fpubh.2020.00147","article-title":"New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria","volume":"8","author":"Kamusheva","year":"2020","journal-title":"Front. Public Health."},{"key":"B9","first-page":"22","article-title":"Compliance, treatment adherence and persistence assessment in acromegaly patients \u2013 a systematic review","volume":"22","author":"Kamusheva","year":"2020","journal-title":"Gen Med."},{"key":"B10","unstructured":"VandevaS\n          MU-SofiaAcromegaly \u2013 Clinical Database and Assessment of Some Epidemiological Data2015"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pcad.2020.08.003","article-title":"Medication adherence: importance, issues and policy: a policy statement from the American Heart Association","volume":"64","author":"Pi\u00f1a","year":"2021","journal-title":"Prog Cardiovasc Dis."},{"key":"B12","unstructured":"Adopted in 2020Good Pharmacy Practice"},{"key":"B13","unstructured":"Bulgarian Association of Health P Rofessionals in Nursing \/B A H P N\/Good Healthcare Professionals Practice"},{"key":"B14","unstructured":"2013"},{"key":"B15","unstructured":"2020"},{"key":"B16","unstructured":""},{"key":"B17","unstructured":"Effective 30 April 20132013"},{"key":"B18","unstructured":"Medicinal Products in Human Medicine Act. In force from 13.04.2007"},{"key":"B19","unstructured":"2020"},{"key":"B20","first-page":"9","article-title":"The patients' adherence to therapy","volume":"18","author":"Mitkova","year":"2016","journal-title":"Gen Med."},{"key":"B21","first-page":"29","article-title":"Influence of the therapeutic regime on the compliance with the therapy in patients with chronic diseases in Bulgaria","volume":"2","author":"Mitkova","year":"2017","journal-title":"Soc Med."},{"key":"B22","first-page":"16","article-title":"Antihypertensive therapy from the perspective of patients and payment institution","volume":"2","author":"Mitkova","year":"2020","journal-title":"Cardiovasc Dis."},{"key":"B23","first-page":"10","article-title":"Dulaglutide: therapy for better adherence. K. Feksa. \/\/","volume":"17","author":"Feksa","year":"2019","journal-title":"Diabet i metabolizum"},{"key":"B24","unstructured":"p. 5\n            NashevD\n          INSPIROAdherence to Therapy or the Good, the Bad and the Evil2015"},{"key":"B25","unstructured":"p. 5\n            PetkovaE\n          INSPIROCompliance and Adherence to Asthma Therapy2015"},{"key":"B26","unstructured":"Broshure for Patients With HIV"},{"key":"B27","first-page":"68","article-title":"Adherence to drug treatment","volume":"55","author":"Kaleva","year":"2015","journal-title":"Pediatriia."},{"key":"B28","first-page":"21","article-title":"Anticoagulation with rivaroxaban in daily practice. Adherence to therapy for effective stroke prevention","volume":"13","author":"Krechmar","year":"2015","journal-title":"Diabet i metabolizum."},{"key":"B29","first-page":"26","article-title":"Adherence to therapy is an important factor in asthma control","volume":"19","author":"Kruncheva","year":"2019","journal-title":"MEDINFO."},{"key":"B30","first-page":"18","article-title":"Adherence to the treatment of allergic rhinitis: difficulty and opportunities for improvement. Alergii khipersens","volume":"15","author":"Novakova","year":"2018","journal-title":"Astma."},{"key":"B31","first-page":"1313","article-title":"Compliance and adherence to asthma therapy","volume":"8","author":"Petkova","year":"2015","journal-title":"InSpiro."},{"key":"B32","first-page":"10","article-title":"Improved adherence to antihypertensive therapy reduces complications associated with high blood pressure","volume":"16","author":"Simova","year":"2019","journal-title":"Kardio D."},{"key":"B33","first-page":"13","article-title":"Adherence to treatment in patients with COPD","volume":"8","author":"Titorenkov","year":"2015","journal-title":"InSpiro."},{"key":"B34","first-page":"2","article-title":"COPD: adherence to treatment","volume":"6","author":"Titorenkov","year":"2015","journal-title":"Topmedica."},{"key":"B35","first-page":"30","article-title":"Local therapy of psoriasis - compliance and adherence to treatment","volume":"15","author":"Vasileva","year":"2014","journal-title":"GPNews."},{"key":"B36","first-page":"5","article-title":"Specialists from Central and Eastern Europe for adherence to dual antiplatelet therapy after acute coronary syndrome","volume":"24","author":"Widimsky","year":"2018","journal-title":"Bulg kardiol."},{"key":"B37","first-page":"137","article-title":"Adherence to antihypertensive therapy - the main tool for good control of blood pressure","volume":"21","author":"Yotov","year":"2020","journal-title":"Nauka kardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40360-017-0124-y","article-title":"Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis","volume":"18","author":"Gurel","year":"2017","journal-title":"BMC Pharmacol Toxicol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11102-019-00943-1","article-title":"Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study","volume":"22","author":"C\u00e1mara","year":"2019","journal-title":"Pituitary."},{"key":"B40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.endinu.2018.12.004","article-title":"ACROSTART: a retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly","volume":"66","author":"\u00c1lvarez-Escol\u00e1","year":"2019","journal-title":"Endocrinol Diabetes Nutr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"A64","DOI":"10.1016\/j.jval.2015.03.375","article-title":"Barriers to treatment adherence associated with acromegaly in the United States: provider\u2018s perspective","volume":"18","author":"Liu","year":"2015","journal-title":"Value Health."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2147\/PPA.S119570","article-title":"Communication practices and awareness of resources for acromegaly patients among endocrinologists","volume":"10","author":"Polanco-Briceno","year":"2016","journal-title":"Patient Prefer Adher."},{"key":"B43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1046\/j.1524-4733.2000.34003.x","article-title":"The reliability and validity of the impact on lifestyle questionnaire in patients with acromegaly","volume":"3","author":"Lenderking","year":"2000","journal-title":"Value Health."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12902-018-0231-9","article-title":"Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report","volume":"18","author":"Ciresi","year":"2018","journal-title":"BMC Endocr Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"P687","DOI":"10.1530\/endoabs.63.P687","article-title":"Patient compliance, mainly due to lower socioeconomic status, is the principal predictor of effective acromegaly treatment: data from a single tertiary center","volume":"63","author":"Tsentidis","year":"2019","journal-title":"Endocrine Abstracts."},{"key":"B46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/EJE-14-0844","article-title":"Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey","volume":"172","author":"Sch\u00f6fl","year":"2015","journal-title":"Eur J Endocrinol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-13-0924","article-title":"Patients lost to follow-up in acromegaly: results of the ACROSPECT study","volume":"170","author":"Delemer","year":"2014","journal-title":"Eur J Endocrinol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11102-012-0412-x","article-title":"Acromegalic patients lost to follow-up: a pilot study","volume":"16","author":"Kasuki","year":"2013","journal-title":"Pituitary."},{"key":"B49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.endien.2018.05.015","article-title":"Expert document on management of acromegaly","volume":"8","author":"Bernabeua","year":"2018","journal-title":"Endocrinolog"},{"key":"B50","unstructured":"NICEMedicines Adherence: Involving Patients in Decisions About Prescribed Medicines Supporting Adherence2009"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/PPA.S84887","article-title":"The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences","volume":"9","author":"Plunkett","year":"2015","journal-title":"Patient Prefer Adher."},{"key":"B52","unstructured":"LondonNational Institute for Health and Care Excellence (UK)2019"},{"key":"B53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4321\/S1886-36552010000400001","article-title":"Adherence policy, education and practice - an international perspective","volume":"8","author":"Marie-Schneider","year":"2010","journal-title":"Pharm Pract."},{"key":"B54","unstructured":"Medicaid Program-General Overview"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4321\/S1886-36552010000100001","article-title":"Adherence: a review of education, research, practice, and policy in the United States","volume":"8","author":"Rickles","year":"2010","journal-title":"Pharm Pract."},{"key":"B56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1472-6963-12-98","article-title":"Unintentional non-adherence to chronic prescription medications: how unintentional is it really?","volume":"12","author":"Gadkari","year":"2012","journal-title":"BMC Health Serv Res."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.693409\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T07:10:23Z","timestamp":1626246623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.693409\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":56,"alternative-id":["10.3389\/fpubh.2021.693409"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.693409","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"article-number":"693409"}}